Wednesday, February 10, 2010, 7:55pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Hollis-Eden Pharmaceuticals, Inc. (HEPH)

At 4:59AM SGT: 0.5292 USD   0.00 (0.00%)  
 MORE ON HEPH 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Hollis-Eden Pharmaceuticals, In (NGM:HEPH) Delayed quote dataEdit
Last Trade:0.5292 USD
Trade Time:4:59AM SGT
Change: 0.00 (0.00%)
Prev Close:0.5292
Open:N/A
Bid:0.05 x 1700
Ask:0.99 x 6000
1y Target Est:6.00
Day's Range:N/A - N/A
52wk Range:0.27 - 0.98
Volume:0
Avg Vol (3m):211,276
Market Cap:15.57M
P/E (ttm):N/A
EPS (ttm):-0.613
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add HEPH to Portfolio   Download Data

 HEADLINES 
•Bioterrorism Is Risky Business
at CNBC (Wed, Dec 9)
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Other Events
EDGAR Online (Tue, Nov 17)
•Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
PR Newswire (Mon, Nov 16)
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Financials
EDGAR Online Financials (Fri, Nov 13)
•Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
PR Newswire (Fri, Nov 13)
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modific
EDGAR Online (Thu, Oct 22)
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listin
EDGAR Online (Thu, Sep 17)
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Aug 14)
•HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Stateme
EDGAR Online (Tue, Jun 16)
More Headlines for HEPH...
 ANALYST 
EPS Est (next year) (Dec-09) :N/A
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due t...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices